Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie Amass

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
The American Journal of Drug and Alcohol Abuse|December 7, 2010
Delay-discounting among homeless, out-of-treatment, substance-dependent men who have sex with menRhodri Dierst-Davies, Cathy J Reback, James A Peck, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 22, 2022
A natural history analysis of asymptomatic <i>TTR</i> gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)Teresa Coelho, Isabel Conceição, Márcia Waddington-Cruz, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 1, 2017
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 yearsFabio A Barroso, Daniel P Judge, Ben Ebede, et al.
Muscle & Nerve|June 9, 2016
Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathyHartmut H-J Schmidt, Fabio Barroso, Alejandra González-Duarte, et al.
Journal of Cardiac Failure|June 23, 2024
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Pablo Garcia-Pavia, Arnt V Kristen, Brian Drachman, et al.
Journal of the Peripheral Nervous System : JPNS|December 15, 2015
"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathyIsabel Conceição, Alejandra González-Duarte, Laura Obici, et al.
Cardiology and Therapy|March 24, 2024
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid CardiomyopathyNicholas Streicher, Leslie Amass, Rong Wang, et al.
Orphanet Journal of Rare Diseases|February 10, 2019
Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case seriesMárcia Waddington-Cruz, Hartmut Schmidt, Marc F Botteman, et al.
Addiction (Abingdon, England)|April 21, 2010
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusersSandra D Comer, Maria A Sullivan, Suzanne K Vosburg, et al.
Muscle & Nerve|December 7, 2017
Estimating the global prevalence of transthyretin familial amyloid polyneuropathyHartmut H Schmidt, Márcia Waddington-Cruz, Marc F Botteman, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
The American Journal of Drug and Alcohol Abuse|December 7, 2010
Delay-discounting among homeless, out-of-treatment, substance-dependent men who have sex with menRhodri Dierst-Davies, Cathy J Reback, James A Peck, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 22, 2022
A natural history analysis of asymptomatic <i>TTR</i> gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)Teresa Coelho, Isabel Conceição, Márcia Waddington-Cruz, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 1, 2017
Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 yearsFabio A Barroso, Daniel P Judge, Ben Ebede, et al.
Muscle & Nerve|June 9, 2016
Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathyHartmut H-J Schmidt, Fabio Barroso, Alejandra González-Duarte, et al.
Journal of Cardiac Failure|June 23, 2024
Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Pablo Garcia-Pavia, Arnt V Kristen, Brian Drachman, et al.
Journal of the Peripheral Nervous System : JPNS|December 15, 2015
"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathyIsabel Conceição, Alejandra González-Duarte, Laura Obici, et al.
Cardiology and Therapy|March 24, 2024
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid CardiomyopathyNicholas Streicher, Leslie Amass, Rong Wang, et al.
Orphanet Journal of Rare Diseases|February 10, 2019
Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case seriesMárcia Waddington-Cruz, Hartmut Schmidt, Marc F Botteman, et al.
Addiction (Abingdon, England)|April 21, 2010
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusersSandra D Comer, Maria A Sullivan, Suzanne K Vosburg, et al.
Muscle & Nerve|December 7, 2017
Estimating the global prevalence of transthyretin familial amyloid polyneuropathyHartmut H Schmidt, Márcia Waddington-Cruz, Marc F Botteman, et al.
Pageof 5